Relmada Therapeutics, Inc. RLMD Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s total operating expenses?
- Relmada Therapeutics, Inc. (RLMD) reported total operating expenses of $19.46M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s total operating expenses changed year-over-year?
- Relmada Therapeutics, Inc.'s total operating expenses increased by 6.8% year-over-year, from $18.22M to $19.46M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s total operating expenses?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s total operating expenses has grown at a -17.2% compound annual growth rate (CAGR), from $125.7M to $59.1M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.